Dermatology

Our dermatology capabilities 

Our dermatology solutions bring together state-of-the-art ex vivo, in vivo and in vitro methodologies to advance your understanding of skin health and disease. With a broad methodical spectrum, we enable testing of compounds, substances and therapeutic targets — individually or in combination.

Target identification and validation:

• Functional genomics (CRISPR, RNAi) for gene editing
• Pathway analysis and disease-relevant target exploration.

Preclinical modelling:

• In vitro assays and ex vivo human skin explants
• In vivo models for various skin diseases.

Biomarker discovery: identification of predictive, diagnostic and response biomarkers.

Innovative approaches for precision medicine 

Our dermatology platforms enable precision medicine by: 

• Utilising human skin explants and 3D models to mimic clinical conditions.
• Applying advanced bioinformatics to identify therapeutic targets. 
• Customising therapeutic approaches to individual patient profiles and disease phenotypes.

Dermatology technology platform 

We leverage advanced technologies to deliver impactful results. 

In vitro models: 

• Primary keratinocytes and fibroblasts 
• iPSC-derived cells (fibroblasts) 
• Standardised scratch and wound healing assays.

Ex vivo models: human skin explants for ex vivo studies.
 
Advanced analytics:

• Imaging systems for histological and morphological analyses
• Multi-omics platforms for biomarker profiling
• Cytokine and chemokine quantification using flow cytometry.

Tailored services for drug development: We provide flexible and customised study solutions to meet specific research needs. 

Efficacy studies: 

• Evaluation of anti-inflammatory and regenerative therapies 
• PK/PD studies in preclinical models.

Mechanistic studies: 

• Investigation of skin barrier restoration and immune modulation 
• Mode-of-action studies using advanced imaging and multi-omics.